Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Acumen Pharmaceuticals, Inc.

NASDAQ: ABOS · Life Sciences · 5 alerts · CIK 1576885

Share price
$0.2160Close, Nov 16
Market cap
$15.6M
Shares outstanding
72.33MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Acumen Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:04 PM ET 10-Q
Financial Results

Acumen Pharmaceuticals Q3 2026 Results: Net Loss of $25.4M, Loss Narrows

For the nine months ended September 30, 2026, Acumen Pharmaceuticals reported a net loss of $78.8 million, an improvement from the $96.2 million loss in the prior year period, primarily driven by a decrease in research and development expenses. The company's cash, cash equivalents, and marketable securities totaled $78.6 million as of September 30, 2026, down from $116.9 million at the end of 2025.

Key figure
Net loss $25.4M
7:10 AM ET 8-K
Financial Results

Acumen Pharmaceuticals Financial Results

Acumen Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $78.6 million which is expected to fund operations into early 2027. The company announced it expects to report topline results from its ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer’s disease in November 2026.

Term
Q3 2026

“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody.”

Daniel O’Connell, Chief Executive Officer of Acumen

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.